drugset
drugset / Trial / NCT06139302

A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men

NCT06139302 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objectives of this trial are to investigate pharmacokinetics (PK) of R-BI 1015550 in Japanese healthy male subjects following oral administration of two different single BI 1015550 doses.

Timeline

Start
2023-12-20
Primary completion
2024-02-07
Completion
2024-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule 9 mg Oral
Subject Nerandomilast Small molecule 18 mg Oral

Indications

No indication recorded.